HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announce they have entered into a definitive merger agreement (the “Merger Agreement”), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax. HilleVax is a clinical-stage biopharmaceutical company that has focused on developing and commercializing novel vaccines. XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.
Read the full article: HilleVax Enters into a Definitive Agreement to Be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right //
Source: https://www.globenewswire.com/news-release/2025/08/04/3126426/0/en/HilleVax-Enters-into-a-Definitive-Agreement-to-be-Acquired-by-XOMA-Royalty-for-1-95-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html